ECCO'25

Abstract

Section snippets

Duvakitug in Crohn's disease and ulcerative colitis

Duvakitug—an anti-TL1A antibody—was safe and efficacious for induction in patients with Crohn's disease and in those with ulcerative colitis, according to data from the double-blind, phase 2b RELIEVE UCCD basket trial. In the first presentation by Vipul Jairath (London, ON, Canada), 138 adults with moderately to severely active Crohn's disease with inadequate response, loss of response, or intolerance to conventional or advanced therapies, or both, were randomly assigned (1:1:1) to

Lusvertikimab for ulcerative colitis

According to the phase 2 CoTikiS study presented by Arnaud Bourreille (Nantes, France), lusvertikimab—a first-in-class IL-7Rα antagonist—was safe and efficacious in patients with moderately to severely active ulcerative colitis and inadequate response to conventional therapies or failure of advanced therapies, or both. 136 participants were randomly assigned (1:1:1) to receive lusvertikimab 450 mg (n=36), lusvertikimab 850 mg (n=51), or placebo (n=49), intravenously, at weeks 0, 2, and 6. The

Low-emulsifier diet for Crohn's disease

Presented by Aaron Bancil (London, UK), the randomised, double-blind ADDapt trial found that a low-emulsifier diet was safe and efficacious in reducing disease activity in patients with mild to moderately active Crohn's disease. 154 patients with a Crohn's Disease Activity Index (CDAI) of 150–200 and evidence of inflammation (per faecal calprotectin ≥150 μg/g or endoscopy or radiology) were randomly assigned to receive a low-emulsifier diet (intervention; n=79) or the low-emulsifier diet plus